Tiba Biotech

Tiba Biotech is a preclinical biopharmaceutical company developing next-generation RNA vaccines and therapeutics based on a novel dendrimer nanoparticle delivery platform developed at MIT and the Whitehead Institute. Our biodegradable nanoparticle can encapsulate large and complex RNA payloads with relaxed cold-chain requirements and superior safety compared to existing delivery technologies to provide protection against a range of human and animal diseases.

The team comprises the original academic inventors, industry experts, and experienced biotech entrepreneurs. Tiba has raised just under $4M in funding and more than $4M in non-dilutive grants, with an additional $12M in future committed R&D support from government sources or international agencies. Tiba has secured three NIH Small Business Innovation Research (SBIR) grants and two NIH collaborations focused on influenza vaccines under the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. More recently, it was awarded a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines against diseases that pose pandemic risk.